Dr. Arnold is a native New Yorker and studied Cardiology at the Cleveland Clinic in Ohio, USA. As a cancer survivor, she is passionate about Cardio-Oncology : Presently the Medical/ Founding Director of the Cardio-Oncology program and Transitional Clinic for childhood cancer survivors at Lee Health in Florida, a Board of Director member and Chair of the Education Committee for ICOS, and the past chair of the Advocacy for the Cardio-Oncology section of the American College of Cardiology.
Adjunct Professor at the Geriatrics Specialization - School of Medicine - Insubria University – Varese – Italy and Cardiologist in Private Practice - LARC – Turin – Italy. Founder and Chair of the Council on Cardio-Oncology of the ESC. Author of articles and one book and faculty to Congresses related to Cardio-Oncology
Dr. Ana Barac is an Associate Professor of Medicine and Oncology at Georgetown University and director of the MedStar Heart and Vascular Institute's Cardio-Oncology program. She is the immediate past chair of the ACC Cardio-Oncology Council and a co-director of the ACC's Live Course on Cardiovascular Care in Oncology patient. Dr. Barac serves as an Associate Editor of the JACC:Cardio-Oncology and the Journal of Cardiovascular Translational Research.
Dr. Anne Blaes is an Associate Professor in the Division of Hematology and Oncology at the University of Minnesota. She is the section head of Medical Oncology within this division and is Director of Cancer Survivorship Services and Translational Research within the Masonic Cancer Center. She is an active medical oncologist with a special interest in the late effects of cancer therapy, particularly in the area of cardio-oncology. Her research focuses on designing and implementing strategies to help prevent the long term complications of treatments in our cancer survivors, particularly in the areas of cardiovascular health. She is the Chair for the American Society of Clinical Oncology’s Cancer Survivorship Committee, a member of the Executive Board for the Global Cardiooncology Society, associate editor for JACC Cardiooncology, and an active member of the ALLIANCE for Cancer Clinical Trials.
Medical Oncologist, and Medical Director of the Cancer Program and the Marvelle Koffler Breast Centre at Mount Sinai Hospital, Toronto Canada and Senior Scientist at Lunenfeld-Tanenbaum Research Institute. Current President of the Canadian Cardio- Oncology Network who obtained her PhD in Medical Biophysics at Princess Margaret Hospital in Toronto and Medical Degree from University of Toronto where she is an Associate Professor.
Miguel Canales is the Section Chief of Haematology at La Paz University Hospital, Madrid, Spain. He is also an Associate Professor of Health Sciences in the Department of Medicine at the Autonomous University of Madrid, and Director of the Hematopoietic Transplant Programme at La Paz University Hospital, Spain. He began specialising in Haematology and Haemotherapy at La Paz University Hospital and completed his training at the MD Anderson Cancer Center in Houston, Texas, USA in the Department of Lymphoma and Myeloma, under the direction of Professor Fernando Cabanillas. Dr Canales is a Principal Investigator on a number of clinical trials in lymphoma and an expert on haematopoietic stem cell transplantation and cellular therapies, and has authored several books and book chapters on non-Hodgkin and Hodgkin’s lymphoma as well as publishing numerous articles in peer-reviewed journals including Journal of Clinical Oncology, Blood, British Journal of Haematology, Haematologica, Bone Marrow Transplantation and Lancet Haematology.
Dr. Daniela Cardinale is specialized in Cardiology. She holds a PhD in Cardiovascular Physiopathology in 2009. She is currently Director of the Cardioncology Unit of the European Institute of Oncology in Milan. Her professional experience and investigational interests focus on prevention, early detection, monitoring and treatment of cardiotoxicity; screening of cardiotoxicity in patients with cardiac disease; malignant pericardial effusion evaluation and intrapericardial treatment.
Joseph R. Carver, MD, FACC is a Board Certified cardiologist. He is the Founding Editor of the American Journal of Managed Care and was a Senior Corporate Medical Director at Aetna U.S. Healthcare from 1992-2001 where he was responsible for new program development and directed the National Medical Excellence Program. From 1999-2001, he was Co-chairperson of the New Jersey and Michigan Working Groups that established voluntary agreements among the insurers in those states to cover the routine costs of clinical trial participation for cancer patients.
He is one of the Founding Editors of Cardio-oncology Journal.
He currently is the Bernard Fishman Clinical Professor of Medicine at the Abramson Cancer Center of the University of Pennsylvania, the Chief Operating Officer of the Abramson Family Cancer Research Institute of the Abramson Cancer Center of the University of Pennsylvania and the Chief of Staff of the Abramson Cancer Center. He is the director of the Penn Cardio-oncology Center of Excellence and his clinical practice is in the subspecialty of Cardio-oncology. He was the recipient of the IS Ravdin Master Clinician Award at Penn in 2012 and is one of the founding members of Penn Medicine’s Academy of Master Clinicians.
Giuseppe Curigliano, MD PhD, is Associate Professor of Medical Oncology at University of Milano and the Head of the Division of Early Drug Development at European Institute of Oncology, Italy. He has been awarded with the first ESO Umberto Veronesi Award in Vienna in 2017 and with the Fellowship of the European Academy of Cancer Sciences in Paris in 2017. He has contributed to over 380 peer-reviewed publications.
Dr. Andrés J. Daniele is a Head of the Cardio-Oncology Department at the Instituto de Oncología "Ángel H. Roffo", Buenos Aires University. He earned his MD degree at La Plata University and completed his residency in cardiology at Favaloro Foundation.. He developed cardio-oncology in Argentina for ten years and he is actually president of Asociación de Cardio-Oncología de la República Argentina and the International CardiOncology - Chapter Argentina.
Chief of Medical Oncology at La Paz University Hospital. Director of the Innovation Unit at La Paz research institute-idiPAZ. Professor of Medical Oncology and Co-Direction of Medicine Innovation Department,, Autonoma University, Madrid. Spain
Susan Dent is a medical oncologist, associate director of Breast Cancer Clinical Research and co-director of the Duke Cardio-Oncology Program at Duke University, Durham, USA. Her areas of interest include breast cancer, treatment toxicities, and cardiotoxicity. She is the founder and Past-President of the Canadian Cardiac Oncology Network (CCON) and Vice-President of the International Cardio-Oncology Society (ICOS), organizations dedicated to improving our understanding of how cancer treatments impact cardiovascular health with the ultimate goal of preventing cardiotoxicity
Professor Dimitrios Farmakis is a heart failure and cardio-oncology specialist at University of Cyprus and University of Athens Medical Schools, member of ESC bodies on Cardio- Oncology and founding member of Greek Cardio-Oncology bodies. He has a long publication record in top-rated Cardiology journals and ESC textbooks with nearly 9000 citations and an h index of 50.
Dr. Fradley is an Associate Professor of Clinical Medicine at the University of Pennsylvania School of Medicine Division of Cardiology and serves as the medical director of the Cardio-Oncology Center of Excellence. He earned his B.S at Yale University and his MD degree at the Johns Hopkins University School of Medicine. Dr. Fradley completed his residency in internal medicine through the Osler Medical Residency Program at the Johns Hopkins Hospital. He then went on to complete fellowships in both cardiology and electrophysiology at Massachusetts General Hospital. As a trained electrophysioloigst, Dr. Fradley has particular interest in the diagnosis and management of arrhythmic complications associated with traditional and novel cancer therapies.
Cardiac Imaging Unit Coordinator. Ramón y Cajal University Hospital. Madrid. Expert in multimodality imaging including echocardiography, cardiac MR and cardiac CT. Clinical experience in advance echocardiography: 3D, speckle tracking, TEE, stress echo and interventional procedures echo guidance. Cardiac MR in valvular heart diseases and cardiomyopathy and cardiac CT in ischemic and structural heart diseases Multiple talks in national and international imaging congresses, symposia and courses More than 100 published articles in national and international journals Author of multiple chapter books and congress communications
Dr. Joerg Herrmann graduated from Ruhr University in Bochum, Germany and completed his internal medicine residency and cardiovascular diseases and interventional cardiology fellowship at the Mayo Clinic in Rochester, MN. He is a Professor of Medicine and the director of the Cardio-Oncology Clinic at Mayo Clinic. He also serves as an associated editor for several journals including the European Heart Journal.
Zaza Iakobishvili, MD, PhD is a director of Community Cardiology Department in Tel Aviv district of Clalit Health Services and senior cardiologist in Samson Hospital Assuta Ashdod.
He has established first dedicated cardio-oncology clinic in Israel in the Rabin Medical Center in 2013. He is a member of cardio-oncology study group in HFA of ESC.
Dr Kalliopi Keramida is a consultant cardiologist at Attikon University Hospital and she runs the Cardio-Oncology Outpatient Clinic. She is board certified in Cardio-Oncology by International Cardio-Oncology Society (ICOS) (2020) and in Heart Failure (ESC/HFA) (2016). Dr Keramida is a member of the Working Group of Cardio-Oncology of the Hellenic Society of Cardiology.
I am an Associate Professor of Medicine and Epidemiology and physician scientist at the University of Pennsylvania. I lead a NIH-funded translational research program in cardio-oncology focused on determining and modifying individual patient risk. I serve as the Director of the Penn Center for Quantitative Echocardiography; Director of the Penn Cardio-Oncology Center of Excellence; and Editor-in-Chief of JACC: CardioOncology. I am a member of the Sarnoff Scientific Committee and American Society of Clinical Investigation.
Dr Lenihan has been active in cardio-oncology for over 20 years. The main focus of these efforts have included hemodynamic assessments, angiogenic growth factor response, novel cardiac biomarkers as well as optimal methods to prevent or detect heart failure at the earliest stage possible in patients undergoing treatment for cancer. He is the current President of the International Cardio-Oncology Society (ICOS) which is an international professional association whose primary goal is to eliminate cardiac disease as a barrier to effective cancer therapy.
Dr. Jennifer Liu is a Professor of Medicine at the Weill Cornell Medical College and the Director of Cardiac Laboratories at Memorial Sloan Kettering Cancer Center. As a cardio oncologist and echocardiographer, her clinical and research goal is to apply echocardiographic imaging to improve the management of cardiovascular disease of patients during and after cancer therapy through clinical care, research and education.
Dr. Teresa López-Fernández is a Senior Consultant Cardiologist at La Paz University Hospital (IdiPAz Research Institute, Madrid, Spain). She leads the Cardio-Oncology Unit at La Paz University Hospital. She is the president of the Imaging Association of the Spanish Society of Cardiology. She is the founder and chair of the Spanish Cardio-Oncology Working Group at the Spanish Society of Cardiology (SEC). Teresa is the secretary of the European Society of Cardiology (ESC) Council of Cardio-Oncology and a board ICOS member.
Juan C. Lopez-Mattei, MD is a Multimodality Imaging Cardiologist and Associate Professor of Cardiology and Diagnostic Imaging at The University of Texas MD Anderson Cancer Center where he co-directs the Cardiac Radiology Service (Cardiac CT & MRI). He is member of the editorial boards of Journal of Cardiovascular Magnetic Resonance & JACC: CardioOncology. Holds multiple leadership positions in several cardiovascular imaging societies, such as American Society of Echocardiography, Society of Cardiovascular Magnetic Resonance and Society of Cardiovascular Computed Tomography.
Profesor Emeritus Universidad Autónoma de Madrid, Spain.
He has been a Board member of the European Society of Cardiology, Chairman of the Scientific Board of the World Heart Federation, and General Secretary of the Spanish Society of Cardiology.
Fields of research: acute and chronic ischemic heart disease, heart failure and cardiotoxicity
Dr. Alexander Lyon is a Senior Lecturer in Cardiology at Imperial College London and a Consultant Cardiologist at the Royal Brompton Hospital. Alex is the clinical lead for the Cardio-Oncology service at the Royal Brompton Hospital since 2011, and Alex is the current president of the British Cardio-Oncology Society and treasurer of the European Society of Cardiology (ESC) Council of Cardio-Oncology. Alex is a co-investigator of the first Leducq Cardio-Oncology Transatlantic Research Network funded from 2020-2025.
Director of the Arrhythmia and Robotic Electrophysiology Unit, La Paz University Hospital, Madrid, Spain
Professor of Cardiology, Autonoma University, Madrid, Spain
Secretary and President Elect of European Heart Rhythm Association (EHRA). Past chair of the Education, Training Fellows, and Certification Committees of EHRA.
Past President and Secretary of the Arrhythmia and Electrophysiology Section of the Spanish Society of Cardiology
Associate Professor of Medicine
Director, Cardio-Oncology Program
Co-Director, Vanderbilt Program for Optimizing Immuno-oNcology Therapy (V-POINT)
Vanderbilt School of Medicine
I am a cardio-oncologist and myocyte biologist. My NIH-funded laboratory addresses myocardial responses to various stresses including hypoxia, aging and toxins. My laboratory focus has been in delineating the mechanistic underpinnings of cardiovascular toxicities from novel targeted cancer therapies. I believe because of the targeted nature of the toxicities, cardio-oncology can provide insights into novel signaling pathways that are relevant in human cardiovascular biology and pathology.
Dr. Tomas G. Neilan, MD, MPH, FACC, MRCPI
Dr. Neilan is an Associate Professor of Medicine at Harvard Medical School and the director of the Cardio-oncology Program and Co-Director Cardiovascular Imaging Research Center (CIRC), Massachusetts General Hospital. His career has had two major focuses: 1) Understanding how we can improve the cardiovascular care of patients with cancer and 2) The use of advanced imaging to better understand and characterize cardiovascular disease.
Juan Carlos Plana, M.D, is Chief of Cardiology, Chief, Cardiovascular Service Line at Texas Heart Institute / Baylor St. Luke’s Medical Center, Chief of Clinical Operations of the Section of Cardiology, Department of Medicine at Baylor College of Medicine, Director of the Cardio- Oncology Center, and co-Director of the Center for Advanced Cardiac Imaging at Baylor St. Luke’s Medical Center. He is the Don W. Chapman Chair in Cardiology and tenured Associate Professor of Medicine. Dr. Plana is board certified in Cardiology and Echocardiography. Dr. Plana earned his medical degree from Pontificia Universidad Javeriana, Santafé de Bogotá (Colombia). His extensive training included internship, residency, chief resident year and fellowship in Cardiovascular disease and Cardiac Imaging (echocardiography and Nuclear Cardiology) at Baylor College of Medicine. Dr. Plana’s academic career started at the University of Texas MD Anderson Cancer Center where he served as Director of Cardiac Imaging and Medical Director of the Echocardiography laboratory. In 2010, he was recruited to Cleveland Clinic, where he opened and served as Co-Director of the Cardio-Oncology center. Dr. Plana's clinical and research interests include Cardio-Oncology, valvular heart disease, diseases of the aorta, and advanced cardiac imaging. The major focus of Dr. Plana’s clinical and scholarly interest is the development and application of novel echocardiographic techniques in the early detection of cardiac dysfunction caused by chemotherapeutic agents. His work has led to 38 reports published in the peer-reviewed literature, as well as 8 invited reviews and book chapters.
Radiation Oncologist at La Paz University Hospital, Madrid, Spain
Coordinator of the Brachytherapy Unit
Member of the Cardio-Oncology Unit
Former Coordinator at the Spanish Alliance for Colorectal Cancer Prevention
Spanish Cardio-Oncology Working Group Board Member as representative of the Spanish Society of Radiation oncology
I am particularly interested in cardiovascular pharmacology, cardio-immunology, heart failure and drug-induced arrhythmias applied to cardio-oncology. Currently Associate professor leading Pitie-Salpétrière APHP.Sorbonne Cardio-Oncology Program and Paris Est Clinical Investigation Center. Active collaboration with Vanderbilt University Medical Center Cardio-oncology and Pharmacology programs where is still have an adjunct associate professor position.
Dr Susannah Stanway MBChB MSc FRCP MD
Consultant in Medical Oncology Royal Marsden NHS Foundation Trust, Associate Honorary Faculty Institute of Cancer Research, London Biography 2020
Susie is a medical oncology consultant in the Breast Unit at the Royal Marsden Hospital and also practices in the Acute Oncology team at Croydon University Hospital. She has a research interest in cancer survivorship, particularly cardio-oncology. She also works with colleagues in low-and middle-income countries educating and doing collaborative research to improve cancer care.
Dr. Stockerl-Goldstein is a Professor in the Section of BMT/Leukemia, Division of Oncology at Washington University School of Medicine in St. Louis. His areas of research include hematologic malignancies with a specific focus on plasma cell dyscrasias including light chain amyloidosis and multiple myeloma. He is a member of the NCCN Multiple Myeloma Guidelines Panel , the NCCN EHR Oncology Advisory Group and the ASBMT Informatics Committee.
Thomas Suter is board-certified in cardiology and internal medicine and the head of the Department of Internal Medicine at Lindenhofgruppe in Bern, Switzerland. In addition, he leads the Cardio-Oncology Service and is a member of the section for heart failure and cardiac transplantation at the University Hospital Bern. He received his medical degree from the University of Zurich and took residency training in internal medicine and cardiology at University Hospital Zürich, Boston University Medical Center and Brigham and Women’s Hospital, Boston MA. During his cardiology training, he specialized on heart failure and cardiac transplantation. His clinical research during the past 20 years focused on the investigation of cardiovascular side effects of cancer therapeutics. He serves as the vice chair of the Council on Cardio-Oncology of the European Society of Cardiology and on several steering committees of multinational cancer trials. Furthermore, he is directing a basic research lab in which he investigates mechanisms of chemotherapeutic-associated cardiotoxicity. His publications include over 100 articles on heart failure, cancer drug- associated cardiovascular side effects and general cardiology.
Associate Professor, Centre of Postgraduate Medical Education
Specialist of internal medicine and cardiology
ICOS Certified Cardio-Oncologist
Sebastian Szmit graduated from Military Medical Academy, scientific director of the course entitled "Oncology in Cardiology" -obligatory training within specialty program in cardiology in Poland, research coordinator for cardio-oncology in the Polish Lymphoma Research Group (PLRG) and Polish National Oncology Network, honorary member of Cardio-Oncology Society of Southern Africa, member of Executive Advisory Committee of the International Cardio-Oncology Society (ICOS).
Dr. Dinesh Thavendiranathan is a cardiologist at the Toronto General Hospital, University of Toronto. He is an Associate Professor of medicine and a Clinician Investigator. He is also a scientist at the Toronto General Hospital Research Institute. His training was in advanced cardiovascular imaging and his current clinical practice involves work with cardiac MRI, CT, and echocardiography. He is the Director of the Ted Rogers Program in Cardiotoxicity Prevention which focuses on cardiac toxicity from systemic therapies including cancer therapy. His research focus is in the use of advanced cardiac imaging techniques for detection and management of cardiac toxicity. He is an international expert in the field of Cardio-oncology and holds a Canada Research Chair in this field.
Peter van der Meer is professor of cardiology at the University Medical Center Groningen in The Netherlands. The group of Prof. Van der Meer consists of PhD students and post-docs with various backgrounds (biologists, medical doctors, and biomedical-engineers) working on translational research topics to bridge the gap between bench and bedside. His group focuses on understanding the susceptibility to develop heart failure and exploring novel treatment targets and therapies. He is was member of the ESC heart failure guidelines 2016 and is a member of ESC council of cardio-oncology and serves on several steering committees of large morbidity and mortality trials investigating the impact of new and old drugs in patients with heart failure.
Jose L. Zamorano is Professor of Medicine at the University Alcala de Henares, Madrid, Spain, and the Chief of Cardiology at the University Hospital Ramón y Cajal, Madrid, Spain. Professor Zamorano has a broad range of research interests including heart failure, ischaemic heart disease, cardiovascular risk factors and cardiovascular imaging modalities. Within these fields, he has published over 400 articles and 20 books including the European Textbook of Cardiovascular Imaging. His impact factor is >1500 and has a Hirsch Index of 90 with more than 10,000 citations.